Ligand id: 9340

Name: PF-00547659

No information available.
Summary of Clinical Use
PF-00547659 has completed Phase 2 clinical trials for ulcerative colitis and Crohn's disease. Results from Phase 2 ulcerative colitis trial NCT01620255 were published by Vermeire et al. (2017) [3]
Mechanism Of Action and Pharmacodynamic Effects
Lymphocyte homing to specialized lymphoid tissue and mucosal sites of the gastrointestinal tract is determined by the endothelial expression of MAdCAM-1, via interaction with integrin α4β7. The α4β7/MAdCAM-1 interaction is gut-specific. In experimental colitis models blockade of α4β7/MAdCAM-1 interaction reduces lymphocyte recruitment, mucosal damage and clinical signs of disease. PF-00547659 binds human MAdCAM-1 and is expected to act by the same molecular mechanism.